Romeo O'Connor's questions to Immunocore Holdings PLC (IMCR) leadership • Q2 2025
Question
Romeo O'Connor from Trondkepen asked for an update on the brinatofusp programs in lung and ovarian cancer and whether insights from ctDNA and T-cell fitness data are influencing the strategy.
Answer
David Berman, EVP of R&D, described the programs as clinical experiments that are incorporating all learnings. He confirmed that T-cell fitness data supported moving into earlier lines of therapy, and that ctDNA and T-cell fitness remain important biomarkers for informing the ongoing exploration in these indications as well as for the half-life extension version.